Biogen And Samsung Bioepis Launch BYOOVIZ (ranibizumab-nuna)

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
On June 2, 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing Genentech's LUCENTIS®, will be available in the United States on July 1, 2022.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On June 2, 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. announced that BYOOVIZ" (ranibizumab-nuna), a biosimilar referencing Genentech's LUCENTIS®, will be available in the United States on July 1, 2022. BYOOVIZ" is the first FDA approved ophthalmology biosimilar. The FDA approved BYOOVIZ" in September 2021 for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization.

BYOOVIZ" is the first biosimilar launch in the United States under the partnership between Biogen and Samsung Bioepis. According to the press release, the Biogen and Samsung Bioepis commercialization agreement also includes SB15, a biosimilar candidate referencing EYLEA® (aflibercept), with Samsung Bioepis responsible for development, regulatory registration, and manufacture of the products, while Biogen is responsible for commercialization.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More